Lacosamide

Lacosamide, also known as ADD 243037 and SPM 927, is a medication developed by UCB for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain marketed under the trade name Vimpat. Lacosamide is discontinued (DEA controlled substance).

Product information

CAS Number: 175481-36-4

Molecular Weight: 250.29

Formula: C13H18N2O3

Synonym:

Vimpat

Erlosamide

Chemical Name: (2R)-N-benzyl-2-acetamido-3-methoxypropanamide

Smiles: CC(=O)N[C@H](COC)C(=O)NCC1C=CC=CC=1

InChiKey: VPPJLAIAVCUEMN-GFCCVEGCSA-N

InChi: InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

References:

1. Hawkes MA, Fernández Suárez M, Ugarnes G, D'Giano C. Single-dose oral lacosamide in refractory simple partial status epilepticus: case report and review. Clin Neuropharmacol. 2013 Jul-Aug;36(4):138-40.

Products are for research use only. Not for human use.